The US-based Caidya, a global clinical research organisation, has opened a new office in Toronto, Ontario.
The new office will strengthen scientific advancements in the biotech industry, expediting the development and commercialisation of innovative healthcare solutions.
Go deeper with GlobalData
The latest move highlights a critical turning point in Caidya’s expansion objectives, with the company aiming to bolster its position in the booming Canadian biotech sector.
In addition, the opening of its subsidiary, Caidya Canada Limited, will help with the business’s long-term expansion and hiring strategies. Canada is a major world hub in the biotech sector, providing a strong research infrastructure, a pool of highly qualified individuals, and a business-supportive ecosystem.
With a foothold in this ever-changing market, Caidya is looking to improve its clinical trial services offerings and encourage partnerships with regional players.
Dr. Lingshi Tan, CEO of Caidya, said: “We are thrilled to establish Caidya Canada Limited and open our new office in Toronto. This strategic move not only allows us to extend the reach of the Caidya brand but also positions us to tap into the immense potential of the Canadian biotech market. We look forward to collaborating with local stakeholders and contributing to the advancement of healthcare solutions in Canada.”
According to the Government of Canada, Canada is responsible for 4% of global clinical trials, ranks fourth in the number of clinical trials sites, and is the G7 leader in clinical trial productivity (number of trials per population).
